Lung deposition of inhaled colistimethate sodium in cystic fibrosis patients Source: International Congress 2014 – Cystic fibrosis: basic science, physiology and clinical aspects Year: 2014
Efficacy and safety of inhaled antibiotics for chronic pseudomonas infection in cystic fibrosis: Network meta-analysis Source: International Congress 2016 – Cystic fibrosis: inflammation, microbiology, management and monitoring Year: 2016
The use of telehealth system in improving adherence to nebulised treatment in children with cystic fibrosis: Benefits and pitfalls Source: International Congress 2014 – Cystic fibrosis: basic science, physiology and clinical aspects Year: 2014
Ataluren in nonsense mutation cystic fibrosis patients not receiving chronic inhaled tobramycin: Evaluation of exacerbations and lung function Source: International Congress 2016 – Cystic fibrosis: inflammation, microbiology, management and monitoring Year: 2016
Long-term tiotropium bromide therapy was retrospectively analyzed in adults with cystic fibrosis Source: International Congress 2015 – Cystic fibrosis: assessment and treatment Year: 2015
Efficacy of alendronate/colecalciferol/calcium in adults with cystic fibrosis Source: Annual Congress 2010 - Cystic fibrosis: lung disease and much more Year: 2010
Inhalation therapy in cystic fibrosis Source: School Course 2013 - Cystic Fibrosis Year: 2013
Side effects of inhaled tobramycin in patients with Cystic Fibrosis Source: Eur Respir J 2002; 20: Suppl. 38, 526s Year: 2002
Interim data from a long-term safety, tolerability, and efficacy study of liposomal amikacin for inhalation in cystic fibrosis patients with chronic pseudomonas aeruginosa infection Source: International Congress 2014 – Cystic fibrosis: assessment and treatment Year: 2014
Safety and efficacy of pirfenidone in patients with lung fibrosis and TERT mutation Source: International Congress 2016 – IPF pathogenesis Year: 2016
Efficacy and safety of nintedanib in advanced idiopathic pulmonary fibrosis Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016
Lung clearance index predicts pulmonary exacerbations in cystic fibrosis Source: International Congress 2014 – Cystic fibrosis: clinical assessment and treatment Year: 2014
Biomarkers of early relapse of pulmonary exacerbation in cystic fibrosis adult patients Source: Annual Congress 2013 –Cystic fibrosis: clinical problems and microbiology in adults Year: 2013
The efficacity of omaluzimab in a case series with allergic bronchopulmonary aspergillosis and cystic fibrosis Source: International Congress 2015 – Cystic fibrosis: microbiology, immunology and assessment Year: 2015
Omalizumab for the treatment of allergic bronchopulmonary aspergillosis (ABPA) in children with cystic fibrosis (CF) Source: International Congress 2014 – Cystic fibrosis: clinical assessment and treatment Year: 2014
Prescription of Inhaled corticosteroid in non-cystic fibrosis bronchiectasis:a solution or a problem Source: Virtual Congress 2020 – News on clinical evaluation of bronchiectasis, cough and inflammatory disease Year: 2020
Inhaled steroids in children with non-cystic fibrosis bronchiectasis Source: Eur Respir J 2004; 24: Suppl. 48, 392s Year: 2004
Early detection of pulmonary exacerbations in children with cystic fibrosis by electronic home monitoring of symptoms and lung function Source: International Congress 2016 – Cystic fibrosis: monitoring and management Year: 2016
Inhaled mannitol as treatment for children with cystic fibrosis Source: Annual Congress 2008 - The use of inhaled mannitol for assessing airway disease Year: 2008